Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 23.74
- Piotroski Score 3.00
- Grade Buy
- Symbol (CNTX)
- Company Context Therapeutics Inc.
- Price $1.40
- Changes Percentage (-6.67%)
- Change -$0.1
- Day Low $1.27
- Day High $1.43
- Year High $2.75
Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a potent and selective antagonist of the progesterone receptor that is linked to resistance for various classes of cancer therapeutics, such as anti-estrogen therapies across female hormone-dependent cancers. The company is also developing CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of an anti-claudin 6 bispecific monoclonal antibody for gynaecologic cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 03/19/2025
- Fiscal Year End N/A
- Average Stock Price Target $5.25
- High Stock Price Target $6.00
- Low Stock Price Target $4.50
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$1.33
- Trailing P/E Ratio -1.29
- Forward P/E Ratio -1.29
- P/E Growth -1.29
- Net Income $-23,964,211
Income Statement
Quarterly
Annual
Latest News of CNTX
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Context Therapeutics Inc.'s (NASDAQ:CNTX) top owners are individual investors with 52% stake, while 30% is held by private equity firms
Ownership data of Context Therapeutics Inc. reveals that individual investors own 52%, private equity firms own 30%, and institutional investors hold a significant stake. Analyst forecasts and ownersh...
By Yahoo! Finance | 3 months ago -
CNTX Stock Price | Context Therapeutics Inc. Stock Quote (U.S.: Nasdaq) | MarketWatch
Context Therapeutics, Inc. is focused on developing innovative treatments for hormone-driven breast and gynecological cancers. Their lead candidate, ONA-XR, aims to be a complete antagonist of the pro...
By MarketWatch | 4 months ago
